Pre-clinical data [4–6] had prompted evidences of the crucial role of Bortezomib mediated NF-kB inhibition for immune regulation, opening the way for its successful use in steroid refractory cGvHD developing in myeloma patients relapsing after allotransplant [7–10]. In these reports Bortezomib was administered twice-weekly at conventional doses for a median of 6–8 cycles then stopped. There are limited data regarding the feasibility of long-term administration of low-dose Bortezomib with the aim of obtaining persistent inhibition of cGVHD while preserving anti-myeloma effect.
Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report
Federica Cocito;Silvia Mangiacavalli;Paolo Bernasconi;Claudio S. Cartia;Maya Ganzetti;
2017-01-01
Abstract
Pre-clinical data [4–6] had prompted evidences of the crucial role of Bortezomib mediated NF-kB inhibition for immune regulation, opening the way for its successful use in steroid refractory cGvHD developing in myeloma patients relapsing after allotransplant [7–10]. In these reports Bortezomib was administered twice-weekly at conventional doses for a median of 6–8 cycles then stopped. There are limited data regarding the feasibility of long-term administration of low-dose Bortezomib with the aim of obtaining persistent inhibition of cGVHD while preserving anti-myeloma effect.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
